• 668 Citations
  • 14 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. David Waning's research focuses on the emerging importance of bone-muscle crosstalk in aging and disease.

The overarching goal of his research program is to discover and characterize molecular mechanisms that impair musculoskeletal health in disease and aging. Bone and muscle are tightly coupled during growth and development, and also during aging and disease yet the cellular and molecular mechanisms linking these two tissues are not well understood. The Waning lab is developing novel therapeutic approaches that improve musculoskeletal health in pre-clinical models of cancer and chemotherapy-induced sequelae, osteoporosis and aging.

The major aims of Dr. Waning's research are to identify and characterize signal mediators of bone-muscle crosstalk that affect musculoskeletal health. He is especially interested in identifying targets of oxidative stress that affect bone and muscle function; understanding muscle weakness in cachexia; cachexia and the relative contribution of muscle wasting and contractile dysfunction; and bone-muscle crosstalk in rare bone diseases.

Teaching and educational interests

Dr. David Waning is the director of the Cellular and Integrative Physiology Core Option in the Biomedical Sciences Graduate Program at Penn State College of Medicine.

Education/Academic qualification

PhD, Northwestern University

Fingerprint Dive into the research topics where David Waning is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


  • Research Output

    • 668 Citations
    • 14 h-Index
    • 17 Article
    • 4 Review article
    • 2 Short survey

    Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy

    Hain, B. A., Jude, B., Xu, H., Smuin, D. M., Fox, E. J., Elfar, J. C. & Waning, D. L., Feb 1 2020, In : Journal of Bone and Mineral Research. 35, 2, p. 368-381 14 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    A “Connexin” Responsible for the Fatal Attraction of Cancer to Bone

    Waning, D. L., Guise, T. A. & Mohammad, K. S., Jan 8 2019, In : Cell Metabolism. 29, 1, p. 6-8 3 p.

    Research output: Contribution to journalShort survey

  • 2 Scopus citations

    Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles

    Huot, J. R., Essex, A. L., Gutierrez, M., Barreto, R., Wang, M., Waning, D. L., Plotkin, L. I. & Bonetto, A., Apr 2019, In : Cancers. 11, 4, 571.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

    Wright, L. E., Harhash, A. A., Kozlow, W. M., Waning, D. L., Regan, J. N., She, Y., John, S. K., Murthy, S., Niewolna, M., Marks, A. R., Mohammad, K. S. & Guise, T. A., Jan 1 2017, In : Oncotarget. 8, 5, p. 8406-8419 14 p.

    Research output: Contribution to journalArticle

  • 12 Scopus citations

    Bone-induced expression of integrin b3 enables targeted nanotherapy of breast cancer metastases

    Ross, M. H., Esser, A. K., Fox, G. C., Schmieder, A. H., Yang, X., Hu, G., Pan, D., Su, X., Xu, Y., Novack, D. V., Walsh, T., Colditz, G. A., Lukaszewicz, G. H., Cordell, E., Novack, J., Fitzpatrick, J. A. J., Waning, D. L., Mohammad, K. S., Guise, T. A., Lanza, G. M. & 1 others, Weilbaecher, K. N., Nov 15 2017, In : Cancer Research. 77, 22, p. 6299-6312 14 p.

    Research output: Contribution to journalArticle

  • 15 Scopus citations